Evaxion pursues agreement with EIB to bolster equity through conversion of debt into equity
December 17, 2024 08:00 ET
|
Evaxion Biotech
Evaxion and the European Investment Bank (EIB) are in advanced discussions about conversion of €3.5 million out of Evaxion’s €7 million loan with EIB into an equity-type instrumentSuch conversion is...
Evaxion establishes new AI-derived precision cancer vaccine concept
December 12, 2024 08:00 ET
|
Evaxion Biotech
Evaxion’s AI-Immunology™ platform allows for the design of precision cancer vaccines targeting non-conventional ERV tumor antigens shared across patientsNovel preclinical data confirms the...
Evaxion announces 2025 milestones reflecting continued strong strategy execution
December 09, 2024 08:00 ET
|
Evaxion Biotech
With most of Evaxion’s strategic milestones for 2024 now successfully achieved, the company announces milestones for 2025The 2025 key milestones reflect all parts of Evaxion’s strategy for value...
Evaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at ESMO Immuno-Oncology Congress
December 02, 2024 08:00 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, December 2, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present...
Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing
November 13, 2024 08:00 ET
|
Evaxion Biotech
As anticipated, Evaxion has received a delisting determinationThe determination has been appealed by Evaxion requesting a hearing on the matter and seeking another 180-day extension to comply with...
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1
November 12, 2024 08:00 ET
|
Evaxion Biotech
New preclinical data demonstrates that CMV antigens identified with Evaxion’s AI-Immunology™ platform trigger targeted immune responses Results also showcase the successful design of a proprietary...
Evaxion announces business update and third quarter 2024 financial results
October 31, 2024 08:00 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, October 31, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business...
Evaxion to announce business update and third quarter 2024 financial results on October 31
October 28, 2024 08:00 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a...
Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials
October 09, 2024 08:00 ET
|
Evaxion Biotech
Data from three separate clinical trials documents the strong ability of the AI-Immunology™ platform to select clinically relevant vaccine targets Strongest outcomes are generated by the top-ranked...
Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform
October 03, 2024 08:00 ET
|
Evaxion Biotech
Improved precision of the AI-Immunology™ platform in predicting clinically relevant vaccine targets boosts the potential of its AI-derived vaccine candidates The improvement has been achieved through...